The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, ...

Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and ...

Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, ...

A nonprofit called the n-Lorem Foundation is working on developing an individualized treatment that targets the genetic cause ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiac dysfunction is a ...

The Advance-HTN trial compared treatment with the aldosterone synthase inhibitor lorundrostat vs. placebo for blood pressure ...

Posttranscriptional regulation of endothelial nitric oxide synthase (eNOS) expression is an important mechanism by which endothelial cells respond to various physiological and pathophysiological ...

The most notable was phytoene synthase (PSY), the rate-limiting enzyme in carotenoid biosynthesis. The rapid degradation of PSY upon LonB induction in addition to the remarkable stabilization of this ...